Lonza Walkersville announced its new offering of Silensomes™ Human Liver Microsomes (HLM) products – pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping.
CYP phenotyping is a regulatory requirement for new drug candidates to understand their metabolism and to predict drug-drug interactions.
Lonza Walkersville's new Silensomes™ HLM products provide researchers a fully characterized pre-made solution for CYP phenotyping, resulting in more consistent and reliable results.
Lonza's Silensomes™ HLM products include seven cryopreserved human liver microsomes pools that are each pre-treated with a mechanistic-based inhibitor targeting a single CYP enzyme. This chemical inactivation is mechanism-based and irreversible, giving researchers confidence that their results are accurate and reliable. Each of the seven CYP Silensomes™ HLM are packaged as Silensomes™ CYP Phenotyping Kits to include a production-matched control microsome that was treated the same way without the inhibitor. A panel consisting of all seven Silensomes™ HLM with a single matched control is also available.
This new product offering from Lonza is a result of the company's recent agreement with Biopredic International and strengthens Lonza's position as a leading supplier of ADME-Tox products for scientists working in drug development. The addition of Silensomes™ HLM products expands Lonza's extensive ADME-Tox portfolio, which includes fresh and cryopreserved human and animal primary hepatocytes, specialized media and cell culture systems.
"With regulatory authorities specifying CYP phenotyping as part of the drug development process, we wanted to support scientists working in this area by offering more-reliable and easier-to-use models," said Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. "Our Silensomes™ HLM products are supplied in a ready-to-use format and provide a single in vitro solution for CYP phenotyping, helping to simplify drug metabolism studies for researchers."
More information about Lonza's new Silensomes™ HLM products is available on www.lonza.com/silensomes.
Silensomes™ HLM products are produced by and are a trademark of Biopredic International.
Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.
Lonza Contact Information
Lonza Cologne GmbH
Manager Marketing Communications
Tel +49 221 991990
Lonza Group Ltd
Head External Communications
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.